XML 42 R8.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Operating activities      
Net (loss) income $ (348,865) $ 66,858 $ (164,981)
Reconciliation of net loss to net cash used in operating activities:      
Depreciation and amortization 9,184 4,725 3,519
Equity-based compensation 66,018 44,057 34,985
Loss from equity method investment in Casebia   5,467 4,275
Non-cash expense related to ViaCyte transaction     15,582
Gain from consolidation of Casebia   (16,000)  
Other income (expense), non-cash 1,857   (169)
Changes in:      
Accounts receivable (45) (11) 2,538
Prepaid expenses and other assets 17,338 (32,618) (3,342)
Accounts payable and accrued expenses 25,747 5,025 12,110
Deferred revenue 1,381 (45,146) (296)
Deferred rent     (709)
Operating lease assets and liabilities (473) (663)  
Other liabilities, net (10,508) 24,983 249
Net cash (used in) provided by operating activities (238,366) 56,677 (96,239)
Investing activities      
Purchase of property, plant and equipment (18,358) (6,684) (2,773)
Net cash and restricted cash received in connection with the acquisition of Casebia   8,009  
Purchases of marketable securities (593,998)    
Maturities of marketable securities 71,186    
Net cash (used in) provided by investing activities (541,170) 1,325 (2,773)
Financing activities      
Proceeds from issuance of common shares, net of issuance costs 982,289 415,019 307,053
Proceeds from exercise of options and ESPP contributions, net of issuance costs 33,863 15,964 8,938
Repurchase of treasury shares     (57)
Net cash provided by financing activities 1,016,152 430,983 315,934
Effect of exchange rate changes on cash 40 15 (22)
Increase in cash 236,656 489,000 216,900
Cash, cash equivalents and restricted cash, beginning of period 948,812 459,812 242,912
Cash, cash equivalents and restricted cash, end of period 1,185,468 948,812 459,812
Supplemental disclosure of non-cash investing and financing activities      
Property and equipment purchases in accounts payable and accrued expenses 3,412 1,811 334
Equity issuance costs in accounts payable and accrued expenses $ 9,590 $ 295 $ 375